Sartorius and EMBL join forces to offer advanced training and science education
Sartorius is offering its expertise to enhance scientific education and practice.
Sartorius has announced a partnership with the European Molecular Biology Laboratory (EMBL) - one of the Europe’s leading research institutions with global reach. It includes many research sites, such as Heidelberg and Hamburg in Germany, Hinxton in the UK, Grenoble in France and Monterotondo in Italy.
Sartorius has joined the Corporate Partnership Program, EMBL’s platform for fostering advanced training collaboration and activities designed to connect industry to academia. The Corporate Partnership Program includes initiatives such as creating training courses, sponsoring conferences, organizing workshops for professionals and young scientists at the EMBL International Center for Advanced Training, EICAT, which offers numerous courses and conferences each year. In addition, Sartorius will also provide long-term support to EMBL’s school education program by funding travel bursaries each year for teachers to attend courses run by EMBL’s Learning Laboratory for the Life Sciences, ELLS.
Backing this well-known research institution, Sartorius is offering its expertise to enhance scientific education and practice. “By focusing on professional training at all levels, and ensuring that the next generation of young talent has access to the latest knowledge, we aim to support the scientific community to reach its maximum potential,” stated Karen Storm, Vice President of Marketing of the Lab Products & Services Division at Sartorius.
In parallel, EMBL is actively expanding its footprint by strengthening activities beyond the academic sphere into industry. “On behalf of EMBL, we welcome Sartorius to our family of Corporate Partners – working together will enhance our program of internationally renowned events, and we look forward to integrate their technologies and expertise into our offering,” added Prof. Matthias Hentze, Director, EMBL.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.